From neglected-disease approval to a tradable FDA fast-lane pass — simulating PRV issuance, NPV valuation, and open-market sale
Congress created the Priority Review Voucher program to solve a market failure: diseases that kill millions in poor countries, or affect too few children to be commercially attractive, generate little R&D investment because there is no paying market to recoup costs. The PRV dangles a valuable, fully transferable regulatory asset as a bounty for approval in exactly these underserved categories.
Created by the Food and Drug Administration Amendments Act (FDAAA) of 2007 and codified at 21 U.S.C. §360n, the tropical disease PRV rewards approval of a drug or biologic for a disease on FDA's statutory list — currently around 25 conditions including malaria, tuberculosis, leprosy, dengue, Chagas disease, African trypanosomiasis, schistosomiasis, and Ebola/Marburg virus disease.
Eligibility requires that the application be for a "tropical disease product": the active ingredient must not have been previously approved for any indication, and the disease must primarily affect populations in low-resource settings with negligible commercial market in wealthy countries. Ridley, Grabowski, and Moe first proposed the mechanism in a 2006 Health Affairs paper, arguing that a transferable regulatory asset could substitute for the absent commercial incentive without requiring any government appropriation — the "cost" is borne by whichever company's other drug review gets bumped, not by taxpayers.
The first tropical disease PRV was awarded to Novartis in 2009 for Coartem (artemether-lumefantrine, an antimalarial). Since then, roughly two dozen tropical disease vouchers have been issued, several to Bill & Melinda Gates Foundation-funded partnerships and non-profit product-development organizations like Medicines for Malaria Venture.
The Rare Pediatric Disease (RPD) PRV, added by the FDA Safety and Innovation Act (FDASIA) of 2012, targets serious or life-threatening diseases affecting fewer than 200,000 people in the U.S., primarily patients aged birth to 18. Because the program periodically sunsets by statute, Congress has repeatedly reauthorized it — most recently via the Advancing Hope Act of 2020, which extended the authorization for new designations through September 2024, with further extensions since debated in FDA user-fee reauthorization cycles. This on-again, off-again status creates real uncertainty for sponsors planning multi-year rare-disease programs around the incentive.
The Medical Countermeasure (MCM) PRV, created by the 21st Century Cures Act of 2016, rewards approval of countermeasures against "material threat" agents — chemical, biological, radiological, or nuclear agents determined by the Department of Homeland Security to pose a material threat to national security. Unlike the other two categories, MCM PRV eligibility is explicitly tied to biodefense preparedness rather than direct patient population size, and only a handful have been awarded (e.g., for anthrax and smallpox countermeasures).
Across all three programs, the applicant must also meet general conditions: the application must be approved through a standard (non-priority) NDA/BLA pathway, cannot itself already have received priority review absent the voucher program, and the sponsor must not have previously received a PRV for the same active ingredient — closing an obvious loophole where a company could game the system by chunking one drug into serial "new" approvals.
Coartem's 2009 approval produced the first tropical disease PRV under the new program — a single piece of paper, worth nothing to use directly, that within five years would trade hands on the open market for tens of millions of dollars.
The moment FDA signs the qualifying approval letter, it simultaneously issues the Priority Review Voucher — a distinct, freely transferable regulatory instrument entirely separate from the approved drug itself. The voucher has no expiration date, can be sold, traded, or subdivided among corporate entities, and can be redeemed against literally any future marketing application, regardless of therapeutic area.
A Priority Review Voucher is not cash, and it is not a tax credit. It is an administrative instruction to FDA: "treat this future application under the 6-month priority review clock instead of the standard 10-month clock." That is its entire content. It confers no guarantee of approval, no exemption from any safety or efficacy standard, and no ability to skip clinical trials — it only compresses FDA's internal review timeline for whichever single application it is ultimately attached to.
Because the voucher is a right rather than a physical asset, transfer is accomplished by a notification letter to FDA's Center for Drug Evaluation and Research (CDER) identifying the new holder, not by any kind of registered securities transaction. In practice, PRV sales are structured as ordinary corporate asset-purchase agreements, sometimes disclosed in 8-K filings when material to a public company's financials, but the underlying transfer mechanism with FDA itself is simple: whoever holds the voucher at the time of redemption is entitled to use it.
FDA's original 2008 tropical disease PRV guidance and subsequent RPD/MCM guidances all confirm the voucher survives corporate transactions — it can be sold as a stand-alone asset in bankruptcy, acquired via merger, or spun out to a separate holding entity, none of which is true of most other regulatory designations (orphan drug exclusivity, for instance, attaches to the specific approved product and cannot be resold independently).
To actually use a PRV, the holder must notify FDA at least 90 days before submitting the application that will carry the accelerated review — this lead time lets the agency plan review-team staffing, since a priority review pulls a drug ahead of others in the queue and compresses the internal work by roughly 40%.
At submission, the holder pays a dedicated PRV user fee, published annually by FDA and separate from the standard PDUFA application fee — for FY2024 the PRV fee was set at approximately $2.5 million, adjusted yearly for inflation and workload. This fee is intentionally set high: Congress wanted the voucher to be valuable enough to motivate neglected-disease R&D, while ensuring FDA is compensated for the extra reviewer capacity a compressed timeline demands.
One critical nuance: submitting a priority-review application via voucher does not guarantee the review completes in 6 months if the application quality is poor — FDA can still issue Refuse-to-File letters, request major amendments that reset the clock, or ultimately issue a Complete Response Letter instead of approval. The voucher buys a faster clock, not a friendlier verdict.
Because the voucher has no expiration date, some buyers hold it for years as a strategic option — banking it against whichever pipeline asset eventually looks most valuable to accelerate, rather than attaching it to a drug immediately upon purchase.
A PRV is worth nothing in isolation — its value is entirely derivative of whichever future drug it eventually accelerates. Analysts and corporate development teams model voucher value as the expected net present value gained by moving a drug's launch date roughly four months earlier: the delta between a 10-month standard review and a 6-month priority review, converted into pulled-forward revenue.
The standard back-of-envelope valuation treats the voucher as a claim on four extra months of peak-rate sales, discounted for the probability the attached drug is ever approved at all, and for ordinary time-value-of-money considerations:
Voucher Value ≈ Peak Annual Sales × (4/12) × Probability of Success × Discount Factor
Worked example: a buyer is evaluating attaching the voucher to a drug forecast to reach $3.0 billion in peak annual sales, currently at Phase 3 with an estimated 60% probability of approval, and applies a market-risk discount factor of 0.85 to account for commercial execution risk and the chance the 6-month priority clock does not fully translate into 4 months of incremental revenue capture (manufacturing ramp-up, formulary negotiations, and physician-adoption curves rarely accelerate as cleanly as the regulatory clock does):
$3.0B × (4/12) × 0.60 × 0.85 = $510M theoretical NPV uplift
In practice, observed market prices have landed well below such theoretical peaks — historical PRV sales have ranged roughly from $67 million to $350 million — because buyers apply much steeper haircuts than the simple formula suggests: they are paying cash up front for an uncertain future benefit, competing bidders are scarce, and the seller's own information about which specific drug the buyer intends to accelerate is usually withheld during negotiation, limiting the seller's ability to price-discriminate toward the buyer's true reservation value.
The single largest driver of realized voucher value is not the seller's underlying drug at all — it is the buyer's own pipeline. A small biotech that just won tropical disease approval typically has no other near-term blockbuster asset of its own to accelerate; for that company, the voucher's only value is what someone else will pay for it. A large pharma company with a $5 billion-peak-sales drug awaiting standard FDA review, by contrast, may capture hundreds of millions in pulled-forward revenue from the same 4-month acceleration — an enormous asymmetry that is the entire economic logic of a liquid resale market.
Secondary valuation drivers include:
• Patent cliff timing — a voucher is far more valuable when it moves a launch date earlier relative to a looming loss-of-exclusivity date on a competing product, capturing extra months of premium pricing before generic erosion • Competitive launch race — if two companies are racing for the same indication, 4 months can determine which company achieves first-to-market status and captures durable prescriber habit and formulary position • Buyer's cost of capital — companies with high discount rates (smaller, more leveraged biotechs) value near-term cash flow acceleration more than large-cap pharma with cheap capital • Regulatory complexity of the target drug — a priority review is most valuable when the standard review would otherwise be routine (fewer advisory committee delays, less likely to need multiple review cycles), since the 6-month clock can be derailed by the same complications that would have delayed a standard review anyway
The formula rewards blockbusters disproportionately: doubling peak sales from $1.5B to $3.0B roughly doubles the theoretical voucher value, which is exactly why buyers are almost always large pharma companies with late-stage blockbuster candidates, not other small biotechs.
Because the original earner rarely has a blockbuster of its own awaiting review, the rational move is almost always to sell. PRV sales are negotiated privately or run as informal auctions among a handful of large pharma companies, brokered by specialized investment banking teams who track every voucher in circulation and every company's late-stage pipeline gaps.
Unlike a public securities auction, PRV sales are opaque, negotiated transactions between two corporate counterparties, typically advised by boutique life-sciences investment banks that specialize in regulatory-asset trading. The seller — often a small or mid-cap biotech that just earned a voucher through a tropical disease, rare pediatric disease, or MCM approval — engages a banker to solicit indications of interest from a short list of large pharma companies known to have late-stage assets nearing NDA/BLA submission.
Because there are only a handful of vouchers issued per year and only a limited number of buyers with a pipeline asset valuable enough to justify a nine-figure purchase, the market functions more like a thin, illiquid negotiated market than a liquid exchange — prices are sticky to recent comparable transactions ("comps"), and sellers often time their sale announcements around known buyer pipeline catalysts (an upcoming Phase 3 readout, an approaching submission window) to maximize competitive tension.
Publicly disclosed sale prices (subject to rounding and deal-structure caveats, since some deals include contingent milestone payments) have included: BioMarin's 2014 sale to Sanofi/Regeneron for approximately $67.5 million (the first-ever PRV sale, establishing the initial market comp); Knight Therapeutics's 2015 sale to Gilead for approximately $125 million; United Therapeutics's 2015 sale to AbbVie for approximately $350 million (the highest publicly reported price, reflecting AbbVie's urgency around a specific late-stage asset); and Retrophin's 2016 sale to Sanofi for approximately $245 million.
PRV sale prices generally trended downward through the late 2010s and into the 2020s from the early peak years, for several interacting reasons:
• Supply increase — more vouchers being issued each year (particularly from the Rare Pediatric Disease program, which has produced the largest volume) means buyers have more options and less urgency to win any single auction • Statutory uncertainty — the RPD program's repeated sunset-and-reauthorization cycle has periodically created doubt about whether new vouchers will keep being issued, which paradoxically can increase near-term scarcity value for vouchers already in hand while depressing forward-looking willingness to pay a premium • Buyer sophistication — early buyers may have overpaid based on the simple theoretical NPV formula; as more transactions closed and became public comps, buyers converged toward more disciplined, heavily-discounted valuations grounded in realized deal prices rather than theoretical models • Alternative acceleration pathways — FDA's own expansion of Breakthrough Therapy, Fast Track, and Accelerated Approval designations gives sponsors other routes to faster review without needing to buy a voucher at all, reducing the pool of drugs for which a PRV is the marginal deciding factor
Despite the downward drift, the fundamental economics have not changed: a voucher is worth whatever a buyer's own pipeline says it is worth, and a large pharma company staring down a true blockbuster launch race will still pay a substantial premium when the timing is right.
Because the buyer's pipeline value swamps the seller's underlying drug in determining price, two functionally identical vouchers — both earned for, say, a tropical disease antimalarial — can sell for $70M and $300M in the same calendar year, purely as a function of which buyer happened to need the acceleration most urgently.
| Product | Indication | Trial Design | Key Result |
|---|---|---|---|
| BioMarin → Sanofi/Regeneron | 2014, first-ever PRV sale | Vimizim (tropical disease-adjacent pediatric pathway precedent) | ~$67.5M — set the initial market comp |
| Knight Therapeutics → Gilead | 2015 | Rare pediatric disease voucher resale | ~$125M |
| United Therapeutics → AbbVie | 2015, highest reported price | Rare pediatric disease voucher resale | ~$350M |
| Retrophin → Sanofi | 2016 | Rare pediatric disease voucher resale | ~$245M |
The final act converts an abstract financial asset back into something concrete: a faster FDA review clock, applied to the buyer's own drug, translating directly into an earlier launch date and a shifted revenue curve. This is the moment the entire chain of transactions — approval, issuance, valuation, sale — cashes out into an operational outcome.
Under the Prescription Drug User Fee Act (PDUFA) goals negotiated between FDA and industry, a standard New Drug Application or Biologics License Application carries a 10-month review goal measured from the 60-day filing date (itself roughly 60 days after original submission, giving an effective ~12-month timeline from submission to action). A priority review — whether earned organically because the drug offers a significant improvement over existing therapies, or purchased via a redeemed PRV — compresses that same review to a 6-month goal from the filing date.
The practical mechanics inside FDA differ meaningfully between the two tracks: priority review does not mean less scientific scrutiny, but it does mean a compressed internal timeline for medical officer review, statistical review, chemistry-manufacturing-controls review, and (if needed) advisory committee scheduling — all squeezed into 6 months instead of 10. FDA allocates review-team resources accordingly, and sponsors on the priority track are expected to respond to information requests faster to keep pace with the compressed clock.
Redeeming a purchased PRV requires the 90-day advance notice described earlier, plus payment of the separate PRV user fee at submission (on top of the standard PDUFA application fee) — meaning the buyer's all-in cost of acceleration includes both the original purchase price of the voucher itself and this incremental regulatory fee.
The commercial logic that justifies the entire voucher market plays out here: a drug launching 4 months earlier captures roughly 4 extra months of peak-rate sales at the front end of its exclusivity period, before generic or biosimilar competition eventually erodes pricing power. For a blockbuster with $3 billion in steady-state annual sales, 4 months of accelerated capture is worth roughly $1 billion in gross revenue moved earlier on the timeline — even though the true net present value gain is much smaller after discounting, since it is a timing shift rather than incremental total revenue.
Beyond the direct revenue-timing math, an earlier launch date can compound into durable competitive advantages that are hard to capture in a simple NPV formula: first-mover position with prescribers who build habitual prescribing patterns, earlier formulary placement with payers who are slower to displace an incumbent once contracted, and — in head-to-head launch races — the difference between being first-to-market and second-to-market, which can determine long-run market share far beyond the initial 4-month window.
Not every redemption goes smoothly. If FDA identifies deficiencies during the compressed priority review — inspection findings, incomplete data packages, or safety signals requiring further analysis — the agency can still issue a Complete Response Letter on the priority timeline, meaning the buyer spent nine figures on a voucher and gained nothing but a faster "no." This asymmetric downside is why sophisticated buyers apply the market-risk discount factor described in Stage 3 rather than pricing off the naive theoretical maximum.
A drug that might have launched in month 12 under standard review instead launches around month 8 under priority review — a shift of roughly 120 days that, applied to a true blockbuster, can be worth far more to the buyer than the $67M–$350M it paid for the voucher itself, which is exactly why the market exists at all.